These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7574009)

  • 1. Aging alters the pharmacokinetics of pyridostigmine.
    Stone JG; Matteo RS; Ornstein E; Schwartz AE; Ostapkovich N; Jamdar SC; Diaz J
    Anesth Analg; 1995 Oct; 81(4):773-6. PubMed ID: 7574009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of cholinesterase inhibitors.
    Aquilonius SM; Hartvig P
    Clin Pharmacokinet; 1986; 11(3):236-49. PubMed ID: 3524957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A radioimmunoassay for pyridostigmine.
    Meyer HG; Lukey BJ; Gepp RT; Corpuz RP; Lieske CN
    J Pharmacol Exp Ther; 1988 Nov; 247(2):432-8. PubMed ID: 3183945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans.
    Marino MT; Schuster BG; Brueckner RP; Lin E; Kaminskis A; Lasseter KC
    J Clin Pharmacol; 1998 Mar; 38(3):227-35. PubMed ID: 9549661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response curves for edrophonium, neostigmine, and pyridostigmine after pancuronium and d-tubocurarine.
    Donati F; McCarroll SM; Antzaka C; McCready D; Bevan DR
    Anesthesiology; 1987 Apr; 66(4):471-6. PubMed ID: 3565812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridostigmine as an antagonist of d-tubocurarine-induced and pancuronium-induced neuromuscular blockade.
    Ravin MB
    Anesth Analg; 1975; 54(3):317-21. PubMed ID: 1169015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of action of neostigmine and pyridostigmine in the elderly.
    Young WL; Matteo RS; Ornstein E
    Anesth Analg; 1988 Aug; 67(8):775-8. PubMed ID: 3394965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of four cholinesterase inhibitors in rats.
    Yamamoto K; Sawada Y; Iga T
    Biol Pharm Bull; 1995 Sep; 18(9):1292-5. PubMed ID: 8845827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults.
    Rupp SM; Castagnoli KP; Fisher DM; Miller RD
    Anesthesiology; 1987 Jul; 67(1):45-9. PubMed ID: 2886080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentration of pyridostigmine during the antagonism of neuromuscular block.
    Williams NE; Calvey TN; Chan K
    Br J Anaesth; 1983 Jan; 55(1):27-31. PubMed ID: 6821619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective population pharmacokinetic/pharmacodynamic analysis of pyridostigmine, a cholinesterase inhibitor, in Chinese males.
    Seng KY; Loke WK; Moochhala S; Zhao B; Lee JD
    J Pharm Pharmacol; 2009 Sep; 61(9):1187-96. PubMed ID: 19703368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients.
    Matteo RS; Young WL; Ornstein E; Schwartz AE; Silverberg PA; Diaz J
    Anesth Analg; 1990 Oct; 71(4):334-9. PubMed ID: 2169210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolites of neostigmine and pyridostigmine do not contribute to antagonism of neuromuscular blockade in the dog.
    Hennis PJ; Cronnelly R; Sharma M; Fisher DM; Miller RD
    Anesthesiology; 1984 Nov; 61(5):534-9. PubMed ID: 6149707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome.
    Filler G; Gow RM; Nadarajah R; Jacob P; Johnson G; Zhang YL; Christians U
    Pediatrics; 2006 Nov; 118(5):e1563-8. PubMed ID: 17015495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridostigmine kinetics with and without renal function.
    Cronnelly R; Stanski DR; Miller RD; Sheiner LB
    Clin Pharmacol Ther; 1980 Jul; 28(1):78-81. PubMed ID: 6993086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of pyridostigmine in dogs.
    Taylor T; Hawkins DR; Forrest TJ; Chung H
    J Pharm Sci; 1991 Apr; 80(4):353-6. PubMed ID: 1865335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of pancuronium- and pipecuronium-induced neuromuscular block.
    Gyermek L; Cantley EM; Lee C
    Br J Anaesth; 1995 Apr; 74(4):410-4. PubMed ID: 7734260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma clearance of neostigmine and pyridostigmine in the dog.
    Baker PR; Calvey TN; Chan K; Macnee CM; Taylor K
    Br J Pharmacol; 1978 Jul; 63(3):509-12. PubMed ID: 667495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and oral bioavailability of pyridostigmine in man.
    Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO
    Eur J Clin Pharmacol; 1980 Nov; 18(5):423-8. PubMed ID: 7439266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neostigmine, pyridostigmine, and edrophonium as antagonists of pancuronium.
    Ferguson A; Egerszegi P; Bevan DR
    Anesthesiology; 1980 Nov; 53(5):390-4. PubMed ID: 7425377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.